Chief Scientific Officer at Advanced Cell Technology, and Adjunct Professor at Wake Forest University School of Medicine, author Biocentrism: How Life and Consciousness Are the Keys to Understanding the True Nature of the Universe.
Robert Lanza, M. D. is considered one of the leading scientists in the world. He is currently Chief Scientific Office at Advanced Cell Technology, and Adjunct Professor at Wake Forest University School of Medicine. He has hundreds of publications and inventions, and over two dozen scientific books: among them, “Principles of Tissue Engineering,” which is recognized as the definitive reference in the field. Others include One World: The Health & Survival of the Human Species in the 21st Century (Foreword by former President and Nobel laureate Jimmy Carter), and the “Handbook of Stem Cells” and “Essentials of Stem Cell Biology,” which are considered the definitive references in stem cell research.
Dr. Lanza received his BA and MD degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar. He was also a Fulbright Scholar, and was part of the team that cloned the world’s first human embryo for the purpose of generating pluripotent stem cells. Dr. Lanza’s work has been crucial to our understanding nuclear transfer and stem cell biology. In 2001 he was also the first to clone an endangered species (a Gaur), and in 2003, he cloned an endangered wild ox (a Banteng) from the frozen skin cells of an animal that had died at the San Diego Zoo nearly a quarter-of-a-century earlier.
Lanza and his colleagues were also the first to demonstrate that nuclear transplantation could be used to reverse the aging process and to generate immune-compatible tissues, including the first organ tissue-engineered from cloned cells. One of his greatest early achievements came from his demonstration that techniques used in preimplantation genetic diagnosis could be used to generate human embryonic stem (hES) cells without embryonic destruction. He and colleagues have also succeeded in differentiating human pluripotent stem cells into retinal (RPE) cells, and has shown that they provide long-term benefit in animal models of vision loss. Using this technology some forms of blindness may be curable. Lanza’s company is seeking FDA approval to begin clinical trials using them to treat degenerative eye diseases.